These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36978460)

  • 1. Lytic Bacteriophage Is a Promising Adjunct to Common Antibiotics across Cystic Fibrosis Clinical Strains and Culture Models of
    Martin I; Morales S; Alton EWFW; Davies JC
    Antibiotics (Basel); 2023 Mar; 12(3):. PubMed ID: 36978460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against
    Rossitto M; Fiscarelli EV; Rosati P
    Front Microbiol; 2018; 9():775. PubMed ID: 29780361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriophages as potential antibiotic potentiators in cystic fibrosis: A new model to study the combination of antibiotics with a bacteriophage cocktail targeting dual species biofilms of Staphylococcus aureus and Pseudomonas aeruginosa.
    Wang Z; De Soir S; Glorieux A; Merabishvili M; Knoop C; De Vos D; Pirnay JP; Van Bambeke F
    Int J Antimicrob Agents; 2024 Sep; 64(3):107276. PubMed ID: 39009289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells.
    Alemayehu D; Casey PG; McAuliffe O; Guinane CM; Martin JG; Shanahan F; Coffey A; Ross RP; Hill C
    mBio; 2012; 3(2):e00029-12. PubMed ID: 22396480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant
    Racenis K; Rezevska D; Madelane M; Lavrinovics E; Djebara S; Petersons A; Kroica J
    Front Med (Lausanne); 2022; 9():851310. PubMed ID: 35547216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro Newly Isolated Environmental Phage Activity against Biofilms Preformed by
    Fiscarelli EV; Rossitto M; Rosati P; Essa N; Crocetta V; Di Giulio A; Lupetti V; Di Bonaventura G; Pompilio A
    Microorganisms; 2021 Feb; 9(3):. PubMed ID: 33668889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current knowledge in the use of bacteriophages to combat infections caused by Pseudomonas aeruginosa in cystic fibrosis.
    Martínez-Gallardo MJ; Villicaña C; Yocupicio-Monroy M; Alcaraz-Estrada SL; León-Félix J
    Folia Microbiol (Praha); 2023 Feb; 68(1):1-16. PubMed ID: 35931928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.
    Chang RYK; Das T; Manos J; Kutter E; Morales S; Chan HK
    AAPS J; 2019 Apr; 21(3):49. PubMed ID: 30949776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Development of a Bacteriophage Cocktail for Treating Multidrug Resistant
    Camens S; Liu S; Hon K; Bouras GS; Psaltis AJ; Wormald PJ; Vreugde S
    Microorganisms; 2021 Sep; 9(9):. PubMed ID: 34576896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
    Bilal H; Tait JR; Lang Y; Zhou J; Bergen PJ; Peleg AY; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0220321. PubMed ID: 35041509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa.
    Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Chan HK
    Int J Pharm; 2018 Nov; 551(1-2):158-165. PubMed ID: 30223075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms.
    Coulter LB; McLean RJ; Rohde RE; Aron GM
    Viruses; 2014 Oct; 6(10):3778-86. PubMed ID: 25285538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
    Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
    Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phage steering of antibiotic-resistance evolution in the bacterial pathogen,
    Gurney J; Pradier L; Griffin JS; Gougat-Barbera C; Chan BK; Turner PE; Kaltz O; Hochberg ME
    Evol Med Public Health; 2020; 2020(1):148-157. PubMed ID: 34254028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temperate Bacteriophages from Chronic Pseudomonas aeruginosa Lung Infections Show Disease-Specific Changes in Host Range and Modulate Antimicrobial Susceptibility.
    Tariq MA; Everest FLC; Cowley LA; Wright R; Holt GS; Ingram H; Duignan LAM; Nelson A; Lanyon CV; Perry A; Perry JD; Bourke S; Brockhurst MA; Bridge SH; De Soyza A; Smith DL
    mSystems; 2019 Jun; 4(4):. PubMed ID: 31164451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Pseudomonas lytic phages and their application as a cocktail with antibiotics in controlling Pseudomonas aeruginosa.
    Ong SP; Azam AH; Sasahara T; Miyanaga K; Tanji Y
    J Biosci Bioeng; 2020 Jun; 129(6):693-699. PubMed ID: 32107153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.
    Olszak T; Zarnowiec P; Kaca W; Danis-Wlodarczyk K; Augustyniak D; Drevinek P; de Soyza A; McClean S; Drulis-Kawa Z
    Appl Microbiol Biotechnol; 2015 Jul; 99(14):6021-33. PubMed ID: 25758956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
    Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
    Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.